CARE consortium launched to fast-track discovery and development of medicines to treat COVID-19

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With a grant totalling € 77.7 million, CARE is funded by cash contributions from the European Union (EU) and cash and in-kind contributions from eleven European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and three IMI-Associated Partners. CARE is a five-year project comprising 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, Spain, Switzerland, the UK and the US, and is led by VRI-Inserm (French National Institute of Health and Medical Research, Paris, France), Janssen Pharmaceutica, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Beerse, Belgium), and Takeda Pharmaceuticals International, (Zurich, Switzerland). It integrates partners’ COVID-19 projects ongoing since February 2020.

As a member of the CARE consortium, Boehringer Ingelheim will be leading the workstream of the consortium focusing on the development of virus neutralising antibodies. Furthermore, the company will provide antiviral molecules from its legacy HIV and HCV portfolio and small molecule candidates from a complete screen of its molecule library.

“CARE is bringing together 37 partners in an alliance pooling their expertise and know-how around an ambitious five-year work plan to develop therapeutics against the current COVID-19 pandemic. We are very grateful for the financial support provided by the Innovative Medicine Initiative that will enable us to implement this plan,” said Professor Yves Lévy, Executive Director of the VRI-Inserm and CARE coordinator.

CARE aims to maximise synergies and complementarities with other initiatives such as the Gates Foundation-supported COVID-19 Therapeutics Accelerator, MANCO, SCORE, and the ECRAID network, to accelerate the path to providing solutions for the current COVID-19 pandemic as well as future coronavirus outbreaks. After testing in the laboratory, the project will advance the most promising drug candidates to clinical trials in humans.

Clive R Wood, Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim said, “We will work quickly and decisively in an unprecedented spirit of co-operation with our partners in academia and industry to defeat the unprecedented menace of COVID-19 and other serious coronavirus diseases”

“We are very excited to launch the CARE consortium and collaborate with other leading experts to urgently identify new medicines against SARS-CoV-2 and other coronaviruses that may have the potential to cause epidemics. As part of this initiative, we look forward to applying learnings from an ongoing collaboration on COVID-19 with the Rega Institute for Medical Research, part of KU Leuven, to screen a drug repurposing library of thousands of existing drug compounds.” added CARE project leader Marnix Van Loock, Senior Scientific Director and R&D Lead of Emerging Pathogens, Global Public Health, Janssen Pharmaceutica.

Kumar Saikatendu, Director, Global Research Externalization, Takeda said, “CARE aims to create effective therapies with a positive safety profile for current and future coronaviral outbreaks. We hope to move fast and have a meaningful impact in a timely manner.”

Short- and long-term response to COVID-19

CARE aims to create effective therapies with a positive safety profile for the COVID-19 pandemic (drug repositioning) and develop new drugs and antibodies especially designed to tackle the SARS-CoV-2 virus.

The consortium builds on three pillars:

• Drug repositioning, by screening and profiling compound libraries, contributed by partners with the aim of rapidly progressing molecules to advanced stages of clinical testing.

• Small-molecule drug discovery based on in silico screening and profiling of candidate compounds directed against SARS-CoV-2 and future coronavirus targets.

• Virus neutralising antibody discovery using fully human phage and yeast display, immunisation of humanised animal models, patient B cells and in silico

Closely integrated with these pillars are workstreams focusing on the refinement of candidate compounds through a comprehensive medicinal chemistry campaign, systems biology research and pre-clinical and clinical evaluation of molecules from all three pillars. The systems biology work package will investigate the viral pathophysiology to increase understanding of the interplay between virus infection stages and human immune responses. It will identify disease markers, to inform therapy development and improve clinical trial design and monitoring of Phase 1 and 2 trials investigating new therapeutics developed by CARE.